Get 40% Off
🎁 Free Gift Friday: Copy Legendary Investors' Portfolios in One ClickCopy for Free

IBEX shares target cut on slow recovery prospects

EditorAhmed Abdulazez Abdulkadir
Published 19/04/2024, 13:38

On Friday, Baird adjusted its financial outlook for IBEX Ltd. (NASDAQ: NASDAQ:IBEX), reducing the price target to $20 from the previous $21, while maintaining an Outperform rating on the company's stock. The firm's analysis suggests that IBEX presents a favorable risk/reward situation at approximately 6 times the next twelve months' earnings per share (EPS), although it acknowledges that a fundamental recovery might not be immediate.

The firm expects IBEX to report third fiscal quarter revenue and EPS that are slightly below the consensus estimates of Wall Street analysts. Additionally, the firm anticipates that IBEX will reaffirm its guidance for the fiscal year 2024. The slower-than-expected improvement in fundamental trends is attributed to the findings from a recent call center survey indicating a year-over-year deceleration in volumes, marking the toughest trends since the third quarter of 2020.

According to the firm, macroeconomic pressures are playing a significant role in the reduced volumes and revenue for IBEX. Companies are seeking to minimize costs, which may involve relying more on their own internal representatives rather than outsourcing, leading to a shift in volumes to offshore services that typically yield lower revenue.

InvestingPro Insights

As Baird maintains an optimistic stance on IBEX Ltd. with an Outperform rating, it is noteworthy to consider the company's financial health and market performance through the lens of InvestingPro data and insights. IBEX's management has been proactive in enhancing shareholder value, as evidenced by an aggressive share buyback strategy and a high shareholder yield, aligning with Baird's positive outlook.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The company's market capitalization currently stands at $231.25 million, and it is trading at a low P/E ratio of 8.17, which is even more attractive when considering the adjusted P/E ratio for the last twelve months as of Q2 2024 at 7.9. This suggests a potential undervaluation relative to near-term earnings growth, with a PEG ratio of 0.63 indicating that the stock may be poised for growth. Despite recent downward earnings revisions by analysts and a stock price that has seen significant declines over the past three months, InvestingPro Tips highlight that IBEX is predicted to be profitable this year and has been profitable over the last twelve months.

For readers who are considering a deeper dive into IBEX's financials and future prospects, InvestingPro offers additional insights. There are 9 more InvestingPro Tips available that could provide further clarity on the investment potential of IBEX. To access these tips and metrics, visit https://www.investing.com/pro/IBEX and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.